249 related articles for article (PubMed ID: 29376224)
1. Long-term Efficacy of Botulinum Neurotoxin-A Treatment for Essential Blepharospasm.
Lee S; Park S; Lew H
Korean J Ophthalmol; 2018 Feb; 32(1):1-7. PubMed ID: 29376224
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
Ababneh OH; Cetinkaya A; Kulwin DR
Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
[TBL] [Abstract][Full Text] [Related]
3. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm.
Park DI; Shin HM; Lee SY; Lew H
Acta Ophthalmol; 2013 Mar; 91(2):e108-12. PubMed ID: 23425111
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of individualized botulinum neurotoxin type A injection techniques in patients with essential blepharospasm.
Sung Y; Nam SM; Lew H
Korean J Ophthalmol; 2015 Apr; 29(2):115-20. PubMed ID: 25829828
[TBL] [Abstract][Full Text] [Related]
5. Treatment of blepharospasm with botulinum neurotoxin type A: long-term results.
Calace P; Cortese G; Piscopo R; Della Volpe G; Gagliardi V; Magli A; De Berardinis T
Eur J Ophthalmol; 2003 May; 13(4):331-6. PubMed ID: 12872788
[TBL] [Abstract][Full Text] [Related]
6. Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs.
Bentivoglio AR; Fasano A; Ialongo T; Soleti F; Lo Fermo S; Albanese A
Neurotox Res; 2009 Apr; 15(3):224-31. PubMed ID: 19384595
[TBL] [Abstract][Full Text] [Related]
7. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome.
Czyz CN; Burns JA; Petrie TP; Watkins JR; Cahill KV; Foster JA
Am J Ophthalmol; 2013 Jul; 156(1):173-177.e2. PubMed ID: 23541393
[TBL] [Abstract][Full Text] [Related]
8. Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm.
Yoon JS; Kim JC; Lee SY
Korean J Ophthalmol; 2009 Sep; 23(3):137-41. PubMed ID: 19794937
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm.
Nüssgens Z; Roggenkämper P
Graefes Arch Clin Exp Ophthalmol; 1997 Apr; 235(4):197-9. PubMed ID: 9143885
[TBL] [Abstract][Full Text] [Related]
10. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
Badarny S; Susel Z; Honigman S
Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
[TBL] [Abstract][Full Text] [Related]
11. A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm.
Fezza J; Burns J; Woodward J; Truong D; Hedges T; Verma A
J Neurol Sci; 2016 Aug; 367():56-62. PubMed ID: 27423565
[TBL] [Abstract][Full Text] [Related]
12. A direct comparison of onabotulinumtoxina (Botox) and IncobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique.
Saad J; Gourdeau A
J Neuroophthalmol; 2014 Sep; 34(3):233-6. PubMed ID: 24739994
[TBL] [Abstract][Full Text] [Related]
13. Ultra-Long-Term Therapy of Benign Essential Blepharospasm with Botulinumtoxin A-30 Years of Experience in a Tertiary Care Center.
Wabbels B; Fimmers R; Roggenkämper P
Toxins (Basel); 2022 Feb; 14(2):. PubMed ID: 35202148
[TBL] [Abstract][Full Text] [Related]
14. Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects.
Mitsikostas DD; Dekundy A; Hanschmann A; Althaus M; Scheschonka A; Pagan F; Jankovic J
Curr Med Res Opin; 2021 Oct; 37(10):1761-1768. PubMed ID: 34384301
[TBL] [Abstract][Full Text] [Related]
15. Long-term stable efficacy of botulinum toxin A in facial movement disorders with no need for increasing dose.
Badarny S; Ibrahim R; Susel Z; Zaina A; Nasar R; Badarny Y
Medicine (Baltimore); 2021 Jun; 100(25):e26481. PubMed ID: 34160460
[TBL] [Abstract][Full Text] [Related]
16. Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm.
Chundury RV; Couch SM; Holds JB
Ophthalmic Plast Reconstr Surg; 2013; 29(3):205-7. PubMed ID: 23552607
[TBL] [Abstract][Full Text] [Related]
17. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.
Lolekha P; Choolam A; Kulkantrakorn K
Neurol Sci; 2017 Nov; 38(11):2031-2036. PubMed ID: 28884242
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
Cillino S; Raimondi G; Guépratte N; Damiani S; Cillino M; Di Pace F; Casuccio A
Eye (Lond); 2010 Apr; 24(4):600-7. PubMed ID: 19648904
[TBL] [Abstract][Full Text] [Related]
19. Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm.
Snir M; Weinberger D; Bourla D; Kristal-Shalit O; Dotan G; Axer-Siegel R
Am J Ophthalmol; 2003 Jul; 136(1):99-105. PubMed ID: 12834676
[TBL] [Abstract][Full Text] [Related]
20. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.
Pagan FL; Harrison A
Parkinsonism Relat Disord; 2012 Jun; 18(5):441-5. PubMed ID: 22405829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
